Get the Stockscreener App
0.5457
5.68%
-0.0329
After Hours:
.54
-0.0057
-1.04%
AIM ImmunoTech Inc stock is traded at $0.5457, with a volume of 381.83K.
It is down -5.68% in the last 24 hours and down -25.10% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.5786
Open:
$0.58
24h Volume:
381.83K
Relative Volume:
0.09
Market Cap:
$4.45M
Revenue:
$88,000
Net Income/Loss:
$-13.96M
P/E Ratio:
-0.082
EPS:
-6.6545
Net Cash Flow:
$-11.34M
1W Performance:
-1.23%
1M Performance:
-25.10%
6M Performance:
-79.39%
1Y Performance:
+475.60%
1-Day Range:
$0.512
$0.58
1-Week Range:
$0.506
$0.5914
52-Week Range:
$0.506
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.5457 | 4.71M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Provides Routine Update on Annual Filings - The Manila Times
Aim Immunotech Provides Routine Update On Annual Filings - TradingView — Track All Markets
AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks
AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget
AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com
AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView — Track All Markets
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan
AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - ChartMill
AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan
AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Why did AIM stock more than double in pre-market today? - msn.com
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval - MEXC
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):